- Home
- BHV vs LSTA Comparison
BHV vs LSTA Comparison
Compare BHV & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHV | LSTA |
|---|---|---|
| Founded | 2002 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 16.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BHV | LSTA |
|---|---|---|
| Price | $10.64 | $4.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 3.5K | ★ 395.2K |
| Earning Date | 01-01-0001 | 02-27-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.85 | $1.81 |
| 52 Week High | $12.08 | $4.89 |
Technical Indicators
Market Signals| Indicator | BHV | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 77.06 |
| Support Level | $10.69 | $4.51 |
| Resistance Level | $10.81 | $4.62 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 42.37 | 22.95 |
Price Performance
Historical ComparisonAbout BHV BlackRock Virginia Municipal Bond Trust
Blackrock Virginia Municipal Bond Trust is a perpetual closed-end municipal bond fund. Its objective is to provide current income exempt from regular Federal income taxes and Virginia personal income taxes.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.